An Act Adopting The Human Cell Product Labeling Act.
Summary
SB 152 would require businesses operating in Connecticut to give consumers a clear and reasonable warning before exposing them to any product that the business knows was developed or tested with human cells. The warning would have to state that the product was developed or tested with human cells and direct the consumer to a website that discloses the origin of the cells, how they were obtained, and the medical or scientific name of the cell line used.
The bill also authorizes civil or criminal penalties for a person who fails to provide the required warning. In effect, it creates a new disclosure regime for products associated with human cell research or testing and would add a compliance obligation for businesses that market or distribute such products in the state.
Impact
If enacted, the bill would amend the Connecticut General Statutes to impose a new labeling and disclosure requirement on businesses that knowingly expose others to products developed or tested with human cells. It would affect manufacturers, distributors, retailers, and other persons doing business in the state that handle covered products, and it would create potential enforcement exposure through civil or criminal penalties for noncompliance.
Sentiment
Based on the bill text alone, the measure appears to be framed as a consumer-notification and transparency bill rather than a broad regulatory restriction. No committee transcript or vote record is available, so there is no recorded legislative debate or voting pattern to indicate support or opposition. The available context suggests the bill was introduced for consideration but has not yet advanced far enough to generate public legislative sentiment in the record provided.
Contention
The main points of potential contention are the scope of the warning requirement, the burden it places on businesses to investigate and disclose scientific sourcing information, and the inclusion of civil or criminal penalties for failure to warn. Supporters would likely emphasize informed consent and transparency, while opponents may argue that the bill is difficult to administer, could be costly or impractical for businesses, and may raise concerns about overbroad disclosure obligations for products linked to biomedical research.